Navigation Links
Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
Date:10/16/2008

ST. LOUIS, Oct. 16 /PRNewswire/ -- ISTO Technologies, Inc., a privately held orthobiologics company, today announced positive preclinical data related to its NuQu(TM) injectable cell-based therapy for spinal disc repair. The data was presented in Toronto, Canada at the 23rd Annual Meeting of the North American Spine Society. Studies carried out at the University of California San Francisco (UCSF) Department of Orthopedics were designed to investigate potential applications of ISTO's core cell-based platform technology (juvenile cartilage cells) as a non-invasive procedure for treatment of degenerative intervertebral disc. In these pre-clinical studies, the disc nucleus from adult pigs was removed and replaced with juvenile chondrocytes in a protein gel carrier.

"We are encouraged by the results of the UCSF preclinical studies and we believe ISTO's cell-based therapy may offer a breakthrough for early non- surgical intervention for patients suffering from back pain," said Mitchell Seyedin, Ph.D., President & CEO.

"Because the disc environment is only conducive to highly specialized cells, the purpose of this preclinical study was to evaluate whether juvenile cartilage cells can effectively replace and regenerate cartilage in the nucleus," said Jeffrey Lotz, Ph.D., Director of the Orthopaedic Bioengineering Laboratory at UCSF. "We are very encouraged by the fact, that in several animal studies, these cells have shown the ability to generate cartilage in the disc nucleus in a predictable and consistent basis," said Dr. Lotz.

NuQu is being developed as a non-invasive treatment for degenerative disc disease for patients who are suffering from low back pain and have failed to respond to conservative therapy. The economic and social impact of back pain due to disc degeneration places a tremendous burden on patients, the healthcare system and the overall economy. Today, there is no effective treatment for degenerative disc disease.

Disc degeneration, thought to be the major cause of back pain, begins in the nucleus and is accompanied by cell death and tissue destruction. Cartilage regeneration is often called the "holy grail" of the orthopedic industry because of its potential to restore function to damaged joints and spinal discs which otherwise have limited healing potential. Cartilage serves as a "shock absorber", protecting all joints including spinal discs from the wear-and-tear experienced during motion.

ISTO Technologies, Inc. is an orthobiologics company focusing on the development of differentiated products for sport medicine, spinal therapy and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.

For additional information, visit ISTO Technologies' website at http://www.istotech.com or contact Scott Gill, Chief Financial Officer, by phone at (314) 995-6049.


'/>"/>
SOURCE ISTO Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
2. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
3. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
4. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
5. Kuvan Receives Positive Opinion From CHMP for European Approval
6. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
7. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Research and Markets has announced the addition of the "Nanobiotechnology ... ... separate comprehensive analytics for the US, Japan , ... and forecasts are provided for the period 2015 through 2022. Also, ... and analytics are derived from primary and secondary research. This report ...
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):